secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001171520-22-000183
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro reports Q4 revenue $4.3M (+15%) and record 2021 revenue $16.3M (+27%)
--------------------------------------------------------------------------------

- Q4 2021 revenue $4.3M (+15% YoY); full-year revenue $16.3M (+27% YoY), seventh consecutive year of growth.
- Biologics & drug delivery revenue $6.8M in 2021 (+31% YoY); supported 929 cases despite COVID.
- Cash and equivalents $54.1M at year-end, up from $20.1M, aided by Feb 2021 public offering raising ~$46.8M net.
- Operating expenses increased to $24.7M (2021) from $15.3M (2020) due to headcount and R&D investments.
- 2022 revenue guidance reaffirmed at $20-22M; progress on pillars including FDA clearance for Array and BCI collab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000117152022000183/0001171520-22-000183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000117152022000183/eps10120.htm
  HTML page:      https://secwatch.observer/filing/0001171520-22-000183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer